|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Sr.No | **FacultyName** | **Publication in Vancouver referencingstyle.** | **PubmedIndexedYes/No** | **Scopus** |
| 1. | Dr. Anjan Kumar Das | Maity S, Chakraborty A, Mahata SK, Roy S, Das AK, Sen M. Wnt5A Signaling Blocks Progression of Experimental Visceral Leishmaniasis. Front Immunol. 2022 Feb 7;13:818266. doi: 10.3389/fimmu.2022.818266. PMID: 35197983; PMCID: PMC8859155. | Yes |  Yes |
| 2 | Dr. Anjan Kumar Das | Khanra S, Das S, Sarraf NR, Datta S, Das AK, Manna M, Roy S. Antimony resistance mechanism in genetically different clinical isolates of Indian Kala-azar patients. Front Cell Infect Microbiol. 2022 Nov 2;12:1021464. doi: 10.3389/fcimb.2022.1021464. PMID: 36405965; PMCID: PMC9667115. | Yes |  Yes |
| 3. | Dr. Anjan Kumar Das | Adhikari, A., Mondal, S., Chatterjee, T. et al. Redox nanomedicine ameliorates chronic kidney disease (CKD) by mitochondrial reconditioning in mice. Commun Biol 4, 1013 (2021). https://doi.org/10.1038/s42003-021-02546-8 |  Yes |  Yes  |
|  | Dr. Anjan Kumar Das | Adhikari A, Mondal S, Das M, Ghosh R, Biswas P, Darbar S, Singh S, Das AK, Bhattacharya SS, Pal D, Mallick AK, Pal SK. Redox Buffering Capacity of Nanomaterials as an Index of ROS-Based Therapeutics and Toxicity: A Preclinical Animal Study. ACS Biomater Sci Eng. 2021 Jun 14;7(6):2475-2484. doi: 10.1021/acsbiomaterials.1c00402. Epub 2021 Jun 1. PMID: 34060316.  | Yes | No |

|  |  |  |  |
| --- | --- | --- | --- |
| **Sl No.** | **Faculty Name** |  **Training** |  **Period** |
| 1. | Dr.Anjan Kumar Das | Basic Course in Biomedical Research | March to June, 2021 |
| 2 | Dr.Anjan Kumar Das | Revised Basic Course Workshop  | August 21 to August 23, 2017.CNMC&H , King George Medical University |
| 3 | Dr.Anjan Kumar Das | Curriculam Implementation Support Program | May 14 to May 16, 2019CNMC&H, King George Medical University |